Cohen RB, Jimeno A, Hreno J, Sun L, Wallén-Öhman M, Millrud CR, Sanfridson A, Garcia-Ribas I. Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors , Invest New Drugs: 2025
Fayette J, Licitra L, Harrington K, Haddad R, Siu LL, Liu YC, Tahara M, Machiels JP, Rischin D, Seiwert TY, Ferris RL, Keilholz U, Psyrri A, Keam B, Bossi P, Metcalf R, Hsieh CY, Clement PMJ, Isaev P, Mudunov A, Dinis J, Hoeben A, Kasper S, Klinghammer K, Hwang M, Blando J, Serrano O, Ruscica D, Cohen RB. INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab Plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma , Clin Cancer Res: 2025
Sannigrahi MK, Raghav L, Rich DJ, Schrank TP, Califano JA, Lukens JN, Sun L, Morgan IM, Cohen RB, Lin A, Liu X, Brown EJ, You J, Mirabello L, Mishra SK, Shimunov D, Brody RM, Pearson AT, Gimotty PA, Diab A, Jalaly JB, Basu D. Tumor-intrinsic and immune-related features associated with treatment failure in human papillomavirus-related oropharyngeal cancer , J Natl Cancer Inst: 2025
Erin M. Bange, MD, MSCE, Kerry Q. Coughlin, MSW, Wenrui Li, PhD, Timothy J. Brown, MD, MSCE, Daniel Ragusano, MPH, Eesha Balar, Dhivya Arasappan, Michelle Nnaji, Elliot Kim, Corey Alban, BSN, RN, Sindhuja Uppuluri, Elizabeth Moriarty, BSN, RN, Tara Bange, MaT, Lindsey Zinck, PhD, RN, OCN, NEA-BC, David Smith, MS, Michael Josephs, James J. Harrigan, MD, PharmD, Roger B. Cohen, MD, Danielle Zubka, RN, Roy Rosin, MBA, Mohan Balachandran, MA, MS, Qi Long, PhD, Andrea Bilger, MPH, Lynn M. Schuchter, MD, Mira Mamtani, MD, MSEd, Lawrence N. Shulman, MD, Carmen E. Guerra, MD, MSCE, and Ronac Mamtani, MD, MSCE A Text Message Intervention to Minimize the Time Burden of Cancer Care
, NEJM Catal Innov Care Deliv
, 6(3): 2025
Stalker M, Qu K, Cohen RB, Mamtani R, Hwang WT, Sun L. "Off-Label" Use of Checkpoint Inhibitors in Patients With Negative or Unknown PD-L1 Status in Advanced Head and Neck Cancer , J Natl Compr Canc Netw, 23: 2025,90-96
Riaz F, Vaughn JL, Zhu H, Dickerson JC, Sayegh HE, Brongiel S, Baldwin E, Kier MW, Zaemes J, Hearn C, Abdelghany O, Cohen RB, Parikh RB, Reuss JE, Prsic E, Doroshow DB. Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis , JCO Oncol Pract: 2025
Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies , Nat Med: 2025
Barsouk A, Elghawy O, Watts A, Reed-Guy L, Tompkins W, Chandrasekhara K, Grady CB, Iams W, Sun F, Liu G, Patel D, Nieva JJ, Marrone KA, Velcheti V, Liu SV, Patil T, Weiss J, Schwartzman W, Villaruz LC, Hermann A, Aisner DL, Hwang WT, Camidge DR, Sun L, Singh AP, Cohen RB, Aggarwal C, Langer CJ, Marmarelis ME. Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis , Lung Cancer: 2025
Elghawy O, Barsouk A, Reed-Guy L, Stalker M, Sussman J, Robinson K, Kosteva J, Singh A, Cohen RB, Langer C, Ciunci C, D'Avella C, Sun L, Marmarelis ME, Aggarwal C. Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy , Clin Lung Cancer: 2024
Elghawy O, Barsouk A, Xu J, Chen S, Cohen RB, Sun L. Real word outcomes of cabozantinib therapy in poorly differentiated thyroid carcinoma , Eur Thyroid J, 13: 2024,e240225
